1. Home
  2. COOK vs IVVD Comparison

COOK vs IVVD Comparison

Compare COOK & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Traeger Inc.

COOK

Traeger Inc.

HOLD

Current Price

$69.10

Market Cap

201.0M

ML Signal

HOLD

Logo Invivyd Inc.

IVVD

Invivyd Inc.

HOLD

Current Price

$0.68

Market Cap

201.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COOK
IVVD
Founded
1985
2020
Country
United States
United States
Employees
N/A
122
Industry
Wholesale Distributors
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
201.0M
201.9M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
COOK
IVVD
Price
$69.10
$0.68
Analyst Decision
Hold
Strong Buy
Analyst Count
5
5
Target Price
$53.00
$8.75
AVG Volume (30 Days)
54.5K
5.2M
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
79.02
EPS
1.08
N/A
Revenue
$559,520,000.00
$53,426,000.00
Revenue This Year
N/A
$61.57
Revenue Next Year
$3.07
$41.42
P/E Ratio
$61.87
N/A
Revenue Growth
N/A
110.47
52 Week Low
$0.48
$0.49
52 Week High
$86.59
$3.07

Technical Indicators

Market Signals
Indicator
COOK
IVVD
Relative Strength Index (RSI) 48.07 32.04
Support Level $60.87 N/A
Resistance Level $76.22 $1.01
Average True Range (ATR) 5.74 0.07
MACD -1.29 -0.01
Stochastic Oscillator 29.91 1.81

Price Performance

Historical Comparison
COOK
IVVD

About COOK Traeger Inc.

Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.

About IVVD Invivyd Inc.

Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.

Share on Social Networks: